Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation study of lomustine with etoposide and cyclophosphamide conditioning before autologous stem cell transplantation in lymphoma
RBR-10bj7s98Phase 1Recruiting
- Sponsor
- Universidade Federal de Juiz de Fora
- Start
- Apr 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lomustine, etoposide and cyclophosphamide in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by Universidade Federal de Juiz de Fora. Primary endpoints: Maximum tolerated dose of lomustine and Dose-limiting toxicity. Started Apr 2019; status: recruiting.
02
Drugs
lomustineetoposidecyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on RBR-10bj7s98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-10bj7s98.